Previous 10 | Next 10 |
Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete response All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO ...
Two Poster Presentations Will Feature Updated Ivonescimab Data from the AK112-201 and AK112-202 Phase II Studies in Advanced or Metastatic NSCLC Patient Populations Posters to be Presented by Dr. Li Zhang and Dr. Jack West on Friday, March 22 in Prague Summit Therapeutics Inc. (...
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26 th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024...
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ:SMMT). Investors who purchased Summit securities are encouraged to obtain additional in...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 4.3% to $0.707999 on volume of 163,563,003 shares PROSHARES TRUST (SQQQ) rose 2.9% to $11.9857 on volume of 127,669,453 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.2% to $4.62 on vol...
2024-02-20 14:03:21 ET More on Summit Therapeutics Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress Financial information for Summit Therapeutics Read the full article on Se...
2024-02-20 13:54:13 ET Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Conference Call February 20, 2024, 09:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Board and CEO Maky Zanganeh - CEO and Presi...
2024-02-20 12:50:54 ET Gainers: Pop Culture Group Co Ltd ( CPOP ) +176% . AgriFORCE Growing Systems ltd ( AGRI ) +95% . Trxade Health ( MEDS ) +92% . Intuitive Machines ( LUNR ) +48% . Iovance Biotherapeutics ( IOVA ) +39% . ...
2024-02-20 07:07:44 ET More on Summit Therapeutics Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress Financial information for Summit Therapeutics Read the full article on Seeking Alpha For further details see: Summit Therapeutics Non-GA...
Actively Enrolling Two Phase III Clinical Studies in NSCLC for Ivonescimab: HARMONi and HARMONi-3 Updated Phase II Data Announced for Ivonescimab Highlighting 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients and mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients ...
News, Short Squeeze, Breakout and More Instantly...
Summit Therapeutics Inc. Company Name:
SMMT Stock Symbol:
NASDAQ Market:
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday. Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply d...
2024-05-07 07:15:07 ET Citigroup analyst issues BUY recommendation for SMMT on May 7, 2024 05:12AM ET. SMMT was trading at $4.47 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with Chemotherapy Achieving 34% Intracranial Responses; Median Intracranial PFS of 19.3 months in NSC...